ロード中...
A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
Vascular endothelial growth factor (VEGF) is expressed in human bladder tumors. A phase II study was conducted to assess the VEGF inhibitor pazopanib in patients with metastatic, urothelial carcinoma. Nineteen patients with one prior systemic therapy were enrolled. No objective responses were observ...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4102930/ https://ncbi.nlm.nih.gov/pubmed/23891158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2013.05.005 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|